Document:

EX-4.1

 Exhibit 4.1 
 Execution version 
 FIRST SUPPLEMENTAL INDENTURE dated
as of March 18, 2013, among GlaxoSmithKline Capital Inc., a corporation organized under the laws of the State of Delaware (the “Company”), GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales,
as guarantor (the “Guarantor”), and Law Debenture Trust Company of New York (as successor to Citibank, N.A.), a company duly organized and existing under the laws of the State of New York (the “Trustee”). 

RECITALS 

WHEREAS, the Company, the Guarantor and Citibank, N.A., a national banking association duly organized and existing under the laws of the
United States (the “Former Trustee”), entered into an indenture, dated as of April 6, 2004 (the “Indenture”), relating to the issuance from time to time by the Company of its Securities; 

WHEREAS, the Company, the Guarantor, the Former Trustee and the Trustee entered into an Instrument of Resignation, Appointment and
Acceptance, dated as of December 27, 2007, whereby the Former Trustee resigned as trustee, and the Trustee was appointed, and accepted its appointment, as trustee under the Indenture; 

WHEREAS, Section 10.01 of the Indenture provides, among other things, that a supplemental indenture may be entered into by the
Company, the Guarantor and the Trustee, without notice to or the consent of any Holders, (i) to establish the terms of Securities of any series; and/or (ii) to make any change that does not materially and adversely affect the rights of any
Holder of Securities outstanding prior to the date of such supplemental indenture; 
 WHEREAS, the Company and the Guarantor
have requested the Trustee to join with it in the execution and delivery of this first supplemental indenture (the “First Supplemental Indenture”) in order to supplement and amend the Indenture, solely with respect to Securities issued on
or after the date hereof, to: (1) amend certain redemption provisions; (2) amend certain covenants of the Company and the Guarantor; and (3) amend the definition of “Event of Default”; in no event will the provisions of this
First Supplemental Indenture affect the interests of the Holders of Securities of any series outstanding prior to the date of this First Supplemental Indenture in any respect; 
 WHEREAS, the Company and the Guarantor have determined that this First Supplemental Indenture complies with said Section 10.01, does not affect the interests of any Holders of Securities outstanding
prior to the date of this First Supplemental Indenture and does not require notice to or the consent of any Holders; and 

WHEREAS, the Company and the Guarantor represent and warrant that all things necessary to make this First Supplemental Indenture a valid
agreement of the Company, the Guarantor and the Trustee, in accordance with the terms of the Indenture, and a valid amendment of and supplement to the Indenture have been done; 
  

 NOW, THEREFORE, THIS FIRST SUPPLEMENTAL INDENTURE WITNESSETH: 

For and in consideration of the premises and the mutual covenants contained herein and in the Indenture and for other good and valuable
consideration, the receipt and sufficiency of which are herein acknowledged, the Company, the Guarantor and the Trustee hereby agree, for the equal and ratable benefit of the Holders, as follows: 

ARTICLE I 

DEFINITIONS 
 SECTION 1.01 Defined Terms. All capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Indenture, as supplemented and amended hereby. All definitions in
the Indenture shall be read in a manner consistent with the terms of this First Supplemental Indenture. 
 SECTION 1.02
Additional Definitions. 
 “Additional Amounts” has the meaning specified in Section 2.01 hereof. 

“EDGAR System” means the EDGAR filing system of the Commission and the rules and regulations pertaining thereto promulgated by the Commission
in Regulation S-T under the Securities Act and the Exchange Act, in each case as the same may be amended or succeeded from time to time (and without regard to format). 
 “Taxes” has the meaning specified in Section 2.01 hereof. 

ARTICLE II 

AMENDMENTS TO THE INDENTURE 
 SECTION 2.01 Amendments to Section 4.05 Relating to Payment of Additional Amounts. Section 4.05 of the Indenture is amended, with respect to Securities outstanding under series created on
or after the date hereof, to read as follows: 
 “Section 4.05 Payment of Additional Amounts. All payments
of Principal and interest in respect of the Securities shall be free and clear of and without withholding or deduction for or on account of any present or future tax, duty, levy, impost, assessment or other governmental charge of any nature
whatsoever imposed or levied by or on behalf of (i) the government of the United Kingdom or of any territory of the United Kingdom or by any authority or agency therein or thereof having the power to tax or (ii) the government of the
United States or of any state or territory of the United States or by any authority or agency therein or thereof having the power to tax (collectively, “Taxes”), except to the extent such Taxes are required to be withheld or deducted by
law or by the interpretation or administration thereof. If either the Company or the Guarantor is so required to withhold or deduct any amount for or on account of Taxes from any payment made in respect of the Securities, the Company or the
Guarantor, as the case may be, shall pay such additional amounts (“Additional Amounts”) as may be necessary such that the net amount received by each Holder (including such Additional Amounts) after such withholding or deduction shall not
be less than the amount such Holder would have received if the Taxes had not been withheld or deducted; provided that no Additional Amounts will be payable with respect to Taxes: 

 (a) that would not have been imposed but for the existence of any present or
former connection between such Holder or beneficial owner of the Securities (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such Holder or beneficial owner, if such Holder or beneficial owner is
an estate, trust, partnership or corporation) and the United Kingdom or the United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including, without limitation, such Holder or
beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national thereof or being or having been
present or engaged in trade or business therein or having or having had a permanent establishment therein; 
 (b)
that are estate, inheritance, gift, sales, transfer, personal property, wealth or similar taxes, duties, assessments or other governmental charges; 
 (c) that are payable other than by withholding from payments of Principal of or interest on the Securities; 
 (d) that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any certification, identification, information, documentation or other reporting
requirement to the extent such compliance is required by applicable law or administrative practice or an applicable treaty as a precondition to exemption from, or reduction in, the rate of deduction or withholding of such Taxes; 

(e) that would not have been imposed but for the presentation of a Security (where presentation is required) for payment
on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; 

(f) that are imposed on a payment to an individual and are required to be made pursuant to European Council Directive
2003/48/EC or any other Directive implementing the conclusions of the ECOFIN Council meeting of November 26-27, 2000 on the taxation of savings income, or any law implementing or complying with, or introduced in order to conform to, such
Directive; 
 (g) that would not have been imposed if presentation for payment of the relevant Securities had
been made to a Paying Agent other than the Paying Agent to which the presentation was made; 
 (h) that are
imposed solely by reason of the Holder or beneficial owner owning or having owned, actually or constructively, 10% or more of the total combined voting power of all classes of the Company’s stock entitled to vote; 

  
 3 

 (i) that would not have been imposed but for a failure by the Holder or
beneficial owner (or any financial institution through which the Holder or beneficial owner holds any Security through which payment on the Security is made) to comply with any certification, information, identification, documentation or other
reporting requirements (including entering into and complying with an agreement with the U.S. Internal Revenue Service) imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code as in effect on the date of issuance of the
Notes or any successor or amended version of such provisions; or 
 (j) any combination of the foregoing clauses
(a) through (i); 
 nor shall Additional Amounts be paid with respect to any payment of the Principal of or interest on any
Security to any such Holder who is a fiduciary or a partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership
or a beneficial owner would not have been entitled to such Additional Amounts had it been the Holder of the Security. 
 The Company shall maintain, in respect of Securities of each series outstanding, at least one Paying Agent located outside the United Kingdom. In the event that a Paying Agent with respect to Securities
of a particular series is maintained in any member state of the European Union, the Company shall maintain a Paying Agent in at least one member state that will not be obliged to withhold or deduct taxes pursuant to any law implementing European
Council Directive 2003/48/EC or any other Directive implementing the conclusions of the ECOFIN Council meeting of November 26-27, 2000 on the taxation of savings income, provided there is at least one member state that does not require a paying
agent to withhold or deduct pursuant to such Directive. 
 The obligation of the Company or the Guarantor, as the
case may be, to pay Additional Amounts if and when due will survive the termination of this Indenture and the payment of all amounts in respect of the Securities.” 
 SECTION 2.02 Amendments to Section 4.08 Relating to Reports by the Company and the Guarantor. Paragraph (a) of Section 4.08 of the Indenture is amended, with respect to Securities
outstanding under series created on or after the date hereof, to read as follows: 
 “(a) file with the Trustee, within 15
days after the Company or the Guarantor, as the case may be, is required to file the same with the Commission, copies of the annual reports and of the information, documents and other reports (or copies of such portions of any of the foregoing as
the Commission may from time to time by rules and regulations prescribe) which the Company or the Guarantor may be required to file with the Commission pursuant to Section 13 or Section 15(d) of the Exchange Act; or, if the Company or the
Guarantor is not required to file information, documents or reports pursuant to either of such Sections, then it will file with the Trustee, in accordance with rules and regulations prescribed from time to time by the Commission, such of the
supplementary and periodic information, documents and reports which may be required pursuant to Section 13 of the Exchange Act in respect of a security listed and registered on a national securities exchange as may be prescribed from time to
time in such rules and regulations; provided that reports, information and documents filed by the Company or the Guarantor with the Commission via the EDGAR System will be deemed filed with the Trustee for purposes of this Section 4.08 as of
the time that such reports, information and documents are filed via the EDGAR System;”. 

  
 4 

 SECTION 2.03 Amendments to Section 7.01 Relating to Events of Default. 

(a) Paragraph (c) of Section 7.01 of the Indenture is amended, with respect to Securities outstanding under series created on
or after the date hereof, to replace the number “60” with “90.” 
 (b) Paragraph (d) of
Section 7.01 of the Indenture is amended, with respect to Securities outstanding under series created on or after the date hereof, to read as follows: 
 “(d) default under any bond, debenture, note or other evidence of indebtedness for money borrowed of the Company or the Guarantor (not including any indebtedness for which recourse is limited to
property purchased) having in any particular case an aggregate outstanding principal amount in excess of £100,000,000 (or its equivalent in any other currency), whether such indebtedness now exists or shall hereafter be created, which default
shall have resulted in such indebtedness becoming or being accelerated and declared due and payable prior to the date on which it would otherwise have become due and payable, without such acceleration having been rescinded or annulled or such
indebtedness having been discharged; provided that there shall not be deemed to be an Event of Default if such acceleration is rescinded or annulled or such payment is made within 10 days after there has been given to the Company and the Guarantor
by the Trustee or to the Company, the Guarantor and the Trustee by the Holders of 25% or more in aggregate principal amount of the Securities of such series a written notice specifying such default and requiring it to be remedied and stating that
such notice is a “Notice of Default” hereunder;”. 
 ARTICLE III 

GENERAL PROVISIONS 
 SECTION 3.01 Trustee Makes No Representation. The recitals contained herein shall be taken as the statements of the Company and the Guarantor, and the Trustee assumes no responsibility for the
correctness of same. The Trustee makes no representation as to the validity of this First Supplemental Indenture. 

SECTION 3.02 Effect of the First Supplemental Indenture. This First Supplemental Indenture supplements the Indenture and shall be a
part, and subject to all the terms, thereof. The Indenture, as supplemented and amended by this First Supplemental Indenture, is in all respects ratified and confirmed, and the Indenture and the First Supplemental Indenture shall be read, taken and
construed as one and the same instrument; provided, however, that any provision in this First Supplemental Indenture which conflicts with any corresponding provision in the Indenture shall replace such conflicting terms in the Indenture in their
entirety, to the extent that such terms relate to any Securities issued hereafter. All provisions included in this First Supplemental Indenture supersede any conflicting provisions included in the Indenture unless not permitted by law. 

  
 5 

 SECTION 3.03 Counterparts. This First Supplemental Indenture may be executed in any
number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. 
 SECTION 3.04 Trust Indenture Act. The Company and the Guarantor hereby certify that this First Supplemental Indenture conforms to the current requirements of the Trust Indenture Act. 

SECTION 3.05 Governing Law; Waiver of Jury Trial. The laws of the State of New York shall govern this First Supplemental Indenture.
Each of the Company, the Guarantor and the Trustee hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this First Supplemental
Indenture. 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be
duly executed, all as of the date first written above. 
  

					
	GLAXOSMITHKLINE CAPITAL INC.,
	as Issuer
		
	By:	 	 /s/ Simon Dingemans

		 	Name:	 	Simon Dingemans
		 	Title:	 	Director
	
	 GLAXOSMITHKLINE PLC,

as Guarantor

		
	By:	 	 /s/ Simon Dingemans

		 	Name:	 	Simon Dingemans
		 	Title:	 	Chief Financial Officer
	
	 LAW DEBENTURE TRUST COMPANY OF NEW YORK,
 as Trustee

		
	By:	 	 /s/ James D. Heaney

		 	Name:	 	James D. Heaney
		 	Title:	 	Managing DirectorEX-10.6

 Exhibit 10.6 

 
 

 
 INCENTIVE STOCK OPTION AGREEMENT 

UNDER THE AEGERION PHARMACEUTICALS, INC. 
 2010 STOCK OPTION AND INCENTIVE PLAN 
 Name of Optionee: 

No. of Option Shares: 
 Option Exercise Price
per Share: $ 
 Grant Date: 

Expiration Date: 
 Pursuant to
the Aegerion Pharmaceuticals, Inc. 2010 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Aegerion Pharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named above an
option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified
above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is
specified herein. 
 1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion
shall have become exercisable according to the vesting schedule below or in accordance with Section 3. Except as set forth in Section 3, and subject to the discretion of the Administrator to accelerate the exercisability schedule, this
Stock Option shall become exercisable in equal monthly installments, rounded down to the nearest whole share of Stock, over [            ] from the Grant Date commencing on
[            ] of the Grant Date.1 
 Once
exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. 

 

	1 	Maximum of $100,000 per year as “incentive stock options” per Section 5(e) of the Plan. 

 2. Manner of Exercise. 

(a) The Optionee may exercise this Stock Option from time to time on or prior to the Expiration Date by giving written notice to the
Company of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased. 

Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified
or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the
Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise
notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option
purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; or
(iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection. 

The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon
(i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of
laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any
subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares
of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the shares attested to. 
 (b) The
shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable
laws or regulations in connection with such issuance and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be
the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent
shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights
with respect to such shares of Stock. 

  
 2 

 (c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. 

(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration
Date hereof. 
 3. Termination of Employment. 
 (a) Termination Due to Death. If the Optionee’s employment terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date shall become fully
exercisable and may thereafter be exercised by the Optionee’s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. 

(b) Termination Due to Disability. If the Optionee’s employment terminates by reason of the Optionee’s Disability (as
defined in the Employment Agreement between the Optionee and the Company dated as of December 1, 2011; the “Employment Agreement”), any portion of this Stock Option outstanding on such date shall become fully exercisable and
may thereafter be exercised by the Optionee for a period of 12 months from the date of termination or until the Expiration Date, if earlier. 
 (c) Termination for Cause. If the Optionee’s employment terminates for Cause (as defined in the Employment Agreement), any portion of this Stock Option outstanding on such date shall terminate
immediately and be of no further force and effect. 
 (d) Termination Without Cause or with Good Reason in Connection with a
Sale Event. [CUSTOMIZE TO REFLECT THE EMPLOYMENT AGREEMENT TERMS OF THE EXECUTIVE OFFICER – DEFAULT PROVISION FOLLOWS:] In connection with a Sale Event (as defined in the Plan), if the Optionee’s employment terminates without Cause or
with Good Reason (in each case, as defined in the Employment Agreement), any portion of this Stock Option which is unvested and outstanding on such date shall vest and become fully exercisable and non-forfeitable; provided that such termination
without Cause or with Good Reason, as the case may be, and the Optionee’s termination date occurs within 18 months after a Sale Event and the Optionee has executed a Release of Claims (as defined in the Employment Agreement), in which case the
Optionee shall have 90 days from such termination date or until the Expiration Date, if earlier, to exercise the Stock Option. 

(e) Other Termination. If the Optionee’s employment terminates for any reason other than in the circumstances above, and
unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until
the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. 

  
 3 

 The Administrator’s determination of the reason for termination of the Optionee’s
employment shall be conclusive and binding on the Optionee and his or her representatives or legatees. 
 4. Incorporation of
Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.

 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any
manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal
representative or legatee. 
 6. Status of the Stock Option. This Stock Option is intended to qualify as an
“incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult
with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements.
To the extent any portion of this Stock Option does not so qualify as an “incentive stock option,” such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift,
transfer or otherwise) of any Option Shares within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this Stock Option, he or she will so
notify the Company within 30 days after such disposition. 
 7. Tax Withholding. The Optionee shall, not later than the
date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law
to be withheld on account of such taxable event. The Company shall have the authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a
number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 
 8. No
Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with
the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time. 
 9. Notices.
Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may
subsequently furnish to the other party in writing. 

  
 4 

 
			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	  

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

					
	  
	 		 	

  
 5 

  
 

 
 NON-QUALIFIED STOCK OPTION AGREEMENT 

FOR NON-EMPLOYEE DIRECTORS 
 UNDER THE AEGERION PHARMACEUTICALS, INC. 
 2010 STOCK OPTION AND INCENTIVE
PLAN 
 Name of Optionee: 
 No. of
Option Shares: 
 Option Exercise Price per Share: $ 
 Grant Date: 
 Expiration Date: 

Pursuant to the Aegerion Pharmaceuticals, Inc. 2010 Stock Option and Incentive Plan as amended through the date hereof (the
“Plan”), Aegerion Pharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named above, who is a Non-Employee Director, an option (the “Stock Option”) to purchase on or prior to the
Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above, that has become
exercisable under Section 1, subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as
amended. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 
 1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth in Section 3, and subject to the discretion
of the Administrator to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to
[                    ]; provided the Optionee continues to be a Non-Employee Director as of such date. 

2. Manner of Exercise. 
 (a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the
Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased. 

 Payment of the purchase price for the Option Shares may be made by one or more of the
following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the
open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee
delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that
in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as
a condition of such payment procedure; (iv) by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value
that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection. 

The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon
(i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of
laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any
subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares
of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. 
 (b) The
shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable
laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be
the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent
shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights
with respect to such shares of Stock. 
 (c) The minimum number of shares with respect to which this Stock Option may be
exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. 

  
 2 

 (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock
Option shall be exercisable after the Expiration Date hereof. 
 3. Termination as a Non-Employee Director. In the event
that the Optionee’s service as a Non-Employee Director ceases because of death, retirement, as defined by the Administrator, or Disability (as defined below), or in the event of a Change of Control (as defined below) that occurs at such time
when the Optionee is serving as a Non-Employee Director, this Stock Option shall become exercisable in full, whether or not exercisable at such time. “Disability” shall mean that the Non-Employee Director, because of illness or incapacity
for ninety (90) consecutive days or an aggregate of six (6) months, is unable to perform his or her principal duties as a director and fails to be nominated or stand for re-election. “Change of Control” shall mean a Sale Event
and any event in which a “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended ) acquires beneficial ownership of 50% or more of the total voting power of the Company. 

If the Optionee ceases to be a Non-Employee Director for any reason other than removal for cause, no further amount shall become
exercisable, but any portion of this Stock Option outstanding on such date, to the extent exercisable, may be exercised (including by his/her legal representative or legatee as the case may be) for a period of three (3) years from the date of
termination or until the Expiration Date, if earlier. In the event the Optionee is removed for cause, all Stock Options (vested and unvested) shall terminate immediately. 
 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of
the Administrator set forth in Section 2(b) of the Plan. 
 5. Transferability. This Agreement is personal to the
Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the
Optionee, and thereafter, only by the Optionee’s legal representative or legatee. 
 6. No Obligation to Continue as a
Director. Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to continuance as a Director. 
 7. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company
or, in either case, at such other address as one party may subsequently furnish to the other party in writing. 
 8.
Amendment. Pursuant to Section 18 of the Plan, the Administrator may at any time amend or cancel any outstanding portion of this Stock Option, but no such action may be taken that adversely affects the Optionee’s rights under this
Agreement without the Optionee’s consent. 

  
 3 

 
			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	  

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

									
	Dated:	 	  
	 		 		 	  

		 		 		 		 	Optionee’s Signature
					
		 		 		 		 	Optionee’s name:

  
 4 

  
 

 
 RESTRICTED STOCK AWARD AGREEMENT 

UNDER THE AEGERION PHARMACEUTICALS, INC. 
 2010 STOCK OPTION AND INCENTIVE PLAN 
 Name of Grantee: 

No. of Shares: 
 Grant Date: 

Pursuant to the Aegerion Pharmaceuticals, Inc. 2010 Stock Option and Incentive Plan (the “Plan”) as amended
through the date hereof, Aegerion Pharmaceuticals, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the
number of shares of Common Stock (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with
respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator. 

1. Acceptance of Award. The Grantee shall have no rights with respect to this Award unless he or she shall have accepted this
Award by (i) signing and delivering to the Company a copy of this Award Agreement, and (ii) delivering to the Company a stock power endorsed in blank. Upon acceptance of this Award by the Grantee, the shares of Restricted Stock so accepted
shall be issued and held by the Company’s transfer agent in book entry form, and the Grantee’s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a
stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. 
 2. Restrictions and Conditions. 
 (a) Any book entries for the shares of
Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. 

(b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by
the Grantee prior to vesting. 

 (c) If the Grantee’s service as a director of the Company is voluntarily or
involuntarily terminated for any reason (other than death, retirement or disability, in each case as defined by the Administrator or the Plan, or a Sale Event) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted
Stock shall immediately and automatically be forfeited and returned to the Company. 
 3. Vesting of Restricted Stock.
The restrictions and conditions in Paragraph 2 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains a board member of the Company or a Subsidiary on such Dates. If a
series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date. 

 

					
	 Number of

Shares Vested
	 	 	 Vesting Date

		
	 	(33 1/3	%) 	 	[1st anniversary of grant date]
	 	(33 1/3	%) 	 	[2nd anniversary of grant date]
	 	(33 1/3	%) 	 	[3rd anniversary of grant date]

 Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions
have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3. 
 If the Grantee’s service as a director of the Company terminates by reason of the Grantee’s death, disability, retirement or a Sale Event, the restrictions and conditions set forth in Paragraph
2 of this Agreement on any portion of the shares of Restricted Stock shall lapse with respect to all such shares of Restricted Stock and all of such shares shall thereafter not be considered Restricted Stock 

4. Dividends. Dividends on Shares of Restricted Stock shall be paid currently to the Grantee. 

5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all
the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified
herein. 
 6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in
any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. 
 7. Tax
Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any
Federal, state, and local taxes required by law to be withheld on account of such taxable event. Except in 

  
 2 

 
the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required minimum tax withholding obligation to be satisfied, in whole or in
part, by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 

8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee may, within 30 days following the
acceptance of this Award as provided in Paragraph 1 hereof, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees
to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such
advisors and not on any statements or representations of the Company or any of its agents with regard to such election. 
 9.
Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one
party may subsequently furnish to the other party in writing. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	  

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

									
	Dated:	 	  
	 		 		 	  

		 		 		 		 	Grantee’s Signature
					
		 		 		 		 	Grantee’s name and address:

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]